Roche commences tender offer for all shares of Poseida Therapeutics (PSTX) Dec 9, 2024 04:30PM
Poseida Therapeutics (PSTX) Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology Dec 9, 2024 12:01PM
Piper Sandler Downgrades Poseida Therapeutics, Inc (PSTX) to Neutral Dec 2, 2024 03:30AM
Poseida Therapeutics (PSTX) to be Acquired by Roche Holdings for $9 Per Share Plus CVR Nov 26, 2024 06:55AM
Poseida Therapeutics, Inc. (PSTX) Tops Q3 EPS by 63c Nov 7, 2024 05:08PM


Nov 5, 2024 04:13PM Poseida Therapeutics (PSTX) to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
Oct 30, 2024 08:15AM H.C. Wainwright Reiterates Buy Rating on Poseida Therapeutics, Inc (PSTX)
Oct 17, 2024 08:02AM Poseida Therapeutics (PSTX) Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
Oct 17, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Poseida Therapeutics, Inc (PSTX)
Oct 15, 2024 08:05AM Poseida Therapeutics (PSTX) Appoints Cynthia Collins to its Board
Sep 30, 2024 07:55AM Piper Sandler Reiterates Overweight Rating on Poseida Therapeutics, Inc (PSTX)
Sep 30, 2024 05:45AM BTIG Reiterates Buy Rating on Poseida Therapeutics, Inc (PSTX)
Sep 27, 2024 04:31PM Poseida Therapeutics (PSTX) Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1
Sep 16, 2024 08:02AM Poseida Therapeutics (PSTX) Receives RMAT Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Aug 5, 2024 04:35PM Poseida Therapeutics (PSTX) Files $300M Mixed Shelf